| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
87,080,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Co.'s compound, batoclimab, is a human, monoclonal antibody targeting the neonatal fragment crystallizable receptor. Co.'s product candidate, batoclimab, has been dosed in small volumes (e.g., two mL) and with a 27-gauge needle, while still generating therapeutically relevant pharmacodynamic activity. Co. is developing batoclimab for Myasthenia Gravis, Thyroid Eye Disease and Warm Autoimmune Hemolytic Anemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,526,316 |
1,977,983 |
| Total Buy Value |
$0 |
$0 |
$58,000,008 |
$60,700,210 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
4 |
| Total Shares Sold |
121,451 |
211,093 |
494,767 |
657,606 |
| Total Sell Value |
$3,709,409 |
$7,040,317 |
$13,330,723 |
$15,815,635 |
| Total People Sold |
7 |
10 |
10 |
10 |
| Total Sell Transactions |
16 |
30 |
46 |
72 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Torti Frank |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
28,400 |
28,400 |
|
- |
|
| Pande Atul |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
24,700 |
24,700 |
|
- |
|
| Roivant Sciences Ltd. |
10% Owner |
– – • |
2020-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
8,773,969 |
47,213,419 |
|
- |
|
| Roivant Sciences Ltd. |
10% Owner |
– – • |
2020-04-16 |
4 |
B |
$14.50 |
$15,000,004 |
D/D |
1,034,483 |
38,439,450 |
2.45 |
- |
|
| Roivant Sciences Ltd. |
10% Owner |
– – • |
2019-12-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
485,000 |
|
- |
|
| Roivant Sciences Ltd. |
10% Owner |
– – • |
2019-12-18 |
4 |
A |
$10.00 |
$369,199,670 |
D/D |
36,919,967 |
37,404,967 |
|
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-12-11 |
4 |
B |
$10.92 |
$344,024 |
I/I |
31,500 |
902,498 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-12-10 |
4 |
B |
$10.38 |
$269,517 |
I/I |
25,971 |
870,998 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-12-06 |
4 |
B |
$10.20 |
$510,125 |
I/I |
50,000 |
845,027 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-12-06 |
4 |
B |
$10.25 |
$4,100,000 |
I/I |
400,000 |
795,027 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-12-05 |
4 |
B |
$10.15 |
$203,000 |
I/I |
20,000 |
395,027 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-12-04 |
4 |
B |
$10.15 |
$203,000 |
I/I |
20,000 |
375,027 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-12-03 |
4 |
B |
$10.21 |
$204,200 |
I/I |
20,000 |
355,027 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-12-02 |
4 |
B |
$10.40 |
$208,000 |
I/I |
20,000 |
335,027 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-11-29 |
4 |
B |
$10.45 |
$281,293 |
I/I |
26,918 |
315,027 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-11-22 |
4 |
B |
$10.54 |
$21,080 |
I/I |
2,000 |
276,109 |
2.58 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-11-21 |
4 |
B |
$10.42 |
$158,299 |
I/I |
15,194 |
274,109 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-11-20 |
4 |
B |
$10.39 |
$309,582 |
I/I |
29,805 |
258,915 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-11-19 |
4 |
B |
$10.25 |
$305,501 |
I/I |
29,805 |
229,110 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-11-18 |
4 |
B |
$10.25 |
$305,501 |
I/I |
29,805 |
199,305 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-11-15 |
4 |
B |
$10.29 |
$133,800 |
I/I |
13,000 |
169,500 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-11-14 |
4 |
B |
$10.17 |
$132,210 |
I/I |
13,000 |
156,500 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-11-13 |
4 |
B |
$10.17 |
$132,210 |
I/I |
13,000 |
143,500 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-11-12 |
4 |
B |
$10.17 |
$1,017,000 |
I/I |
100,000 |
130,500 |
2.66 |
- |
|
| Wong Roderick |
Chief Executive Officer |
• • – |
2019-11-11 |
4 |
B |
$10.18 |
$132,340 |
I/I |
13,000 |
30,500 |
2.66 |
- |
|
182 Records found
|
|
Page 7 of 8 |
|
|
